BLC
MCID: BLD087
MIFTS: 54

Bladder Cancer, Somatic (BLC) malady

Categories: Genetic diseases, Cancer diseases, Nephrological diseases

Aliases & Classifications for Bladder Cancer, Somatic

Aliases & Descriptions for Bladder Cancer, Somatic:

Name: Bladder Cancer, Somatic 54 24 13 38
Bladder Carcinoma 38 12 52 14
Bladder Cancer 66 52 41
Carcinoma of Bladder 12 69
Malignant Neoplasm of Urinary Bladder 69
Urothelial Carcinoma of the Bladder 66
Carcinoma of Urinary Bladder 12
Urinary Bladder Cancer 66
Cancer of the Bladder 29
Carcinoma Bladder 12
Blc 66

Characteristics:

HPO:

32
bladder cancer, somatic:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 54 109800
Disease Ontology 12 DOID:4007
NCIt 47 C4912
MedGen 40 C0005684
MeSH 42 D001749
UMLS 69 C0699885

Summaries for Bladder Cancer, Somatic

MedlinePlus : 41 the bladder is a hollow organ in your lower abdomen that stores urine. bladder cancer occurs in the lining of the bladder. it is the sixth most common type of cancer in the united states. symptoms include blood in your urine a frequent urge to urinate pain when you urinate low back pain risk factors for developing bladder cancer include smoking and exposure to certain chemicals in the workplace. people with a family history of bladder cancer or who are older, white, or male have a higher risk. treatments for bladder cancer include surgery, radiation therapy, chemotherapy, and biologic therapy. biologic therapy boosts your body's own ability to fight cancer. nih: national cancer institute

MalaCards based summary : Bladder Cancer, Somatic, also known as bladder carcinoma, is related to reactive arthritis and linitis plastica, and has symptoms including transitional cell carcinoma of the bladder An important gene associated with Bladder Cancer, Somatic is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Valstar and Estradiol have been mentioned in the context of this disorder. Related phenotypes are Decreased viability and homeostasis/metabolism

Disease Ontology : 12 A urinary bladder cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

Genetics Home Reference : 25 Bladder cancer is a disease in which certain cells in the bladder become abnormal and multiply without control or order. The bladder is a hollow, muscular organ in the lower abdomen that stores urine until it is ready to be excreted from the body. The most common type of bladder cancer begins in cells lining the inside of the bladder and is called transitional cell carcinoma (TCC).

UniProtKB/Swiss-Prot : 66 Bladder cancer: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.

Description from OMIM: 109800

Related Diseases for Bladder Cancer, Somatic

Diseases related to Bladder Cancer, Somatic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 236)
id Related Disease Score Top Affiliating Genes
1 reactive arthritis 30.1 ERBB2 PIK3CA TP53
2 linitis plastica 30.1 CDH1 TP53
3 bladder carcinoma in situ 11.9
4 gall bladder carcinoma in situ 11.7
5 bladder urothelial carcinoma 11.4
6 transitional cell carcinoma 11.1
7 urinary bladder cancer 11.1
8 bladder cancer, childhood 11.0
9 small cell carcinoma of the bladder 10.9
10 chondrodysplasia, blomstrand type 10.8
11 congenital intrauterine infection-like syndrome 10.8
12 band-like calcification with simplified gyration and polymicrogyria 10.8
13 bladder adenocarcinoma 10.8
14 superficial urinary bladder cancer 10.8
15 bladder squamous cell carcinoma 10.8
16 jewett-marshall bladder cancer 10.8
17 13q12.3 microdeletion syndrome 10.5 CDKN1A CDKN2A FGFR3
18 adult syndrome 10.5 KRAS PIK3CA TP53
19 erythrocyte lactate transporter defect 10.5 FGFR3 HRAS KRAS
20 type 1 papillary adenoma of the kidney 10.5 FGFR3 TP53 UPK3A
21 clear cell hidradenoma 10.5 FGFR3 KRT20 TP53
22 spiradenoma 10.5 FGFR3 KRT20 TP53
23 precursor t-lymphoblastic lymphoma/leukemia 10.5 HRAS KRAS PIK3CA
24 kidney clear cell sarcoma 10.5 HRAS KRAS PIK3CA
25 uterine disease 10.5 CDKN2A PIK3CA TP53
26 melanocytic nevus syndrome, congenital, somatic 10.5 FGFR3 HRAS KRAS PIK3CA
27 breast epithelioid hemangioma 10.5 CDKN1A TP53 UPK3A
28 giant cell tumor 10.5 KRAS KRT20 TP53
29 paraphimosis 10.5 CDKN2A KRT20 TP53
30 pelvic inflammatory disease 10.5 HRAS KRAS KRT20
31 spastic ataxia 5 10.5 CDKN2A KRT20 TP53
32 gallbladder pleomorphic giant cell adenocarcinoma 10.5 CDKN2A HRAS TP53
33 adult epithelioid sarcoma 10.5 CDKN2A HRAS TP53
34 papillary adenofibroma 10.5 HRAS KRAS KRT20 TP53
35 tabes dorsalis 10.5 HRAS KRAS KRT20 TP53
36 postpoliomyelitis syndrome 10.5 CDKN2A HRAS KRAS TP53
37 megalencephaly-capillary malformation-polymicrogyria syndrome, somatic 10.5 FGFR3 PIK3CA TP53
38 endometrial squamous cell carcinoma 10.5 CDKN2A RASSF1 TP53
39 anal carcinoma in situ 10.5 CDKN2A TP53 UPK2
40 ossifying fibromyxoid tumor 10.5 CDKN2A HRAS KRAS TP53
41 bronchiolitis obliterans with obstructive pulmonary disease 10.5 CDH1 MKI67 PIK3CA
42 aicardi-goutieres syndrome 10.5 CDKN2A HRAS KRAS TP53
43 arthus reaction 10.4 ERBB2 HRAS KRAS TP53
44 angiolipomatosis, familial 10.4 ERBB2 KRT20 UPK3A
45 ideomotor apraxia 10.4 CDH1 HRAS KRAS TP53
46 striated muscle rhabdoid tumor 10.4 CDKN2A HRAS KRAS
47 basophilic carcinoma 10.4 CDH1 HRAS KRAS TP53
48 spongiotic dermatitis 10.4 ERBB2 HRAS KRAS PIK3CA
49 spastic paraplegia 1 10.4 MKI67 PIK3CA TP53
50 plasmacytoma 10.4 HRAS KRAS TP53

Graphical network of the top 20 diseases related to Bladder Cancer, Somatic:



Diseases related to Bladder Cancer, Somatic

Symptoms & Phenotypes for Bladder Cancer, Somatic

Symptoms by clinical synopsis from OMIM:

109800

Clinical features from OMIM:

109800

Human phenotypes related to Bladder Cancer, Somatic:

32
id Description HPO Frequency HPO Source Accession
1 transitional cell carcinoma of the bladder 32 HP:0006740

GenomeRNAi Phenotypes related to Bladder Cancer, Somatic according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.09 HRAS KRAS PIK3CA DAPK1
2 Decreased viability GR00106-A-0 10.09 KRAS
3 Decreased viability GR00221-A-1 10.09 HRAS CDKN2A PIK3CA FGFR3 CDH1 DAPK1
4 Decreased viability GR00221-A-2 10.09 FGFR3 HRAS TSC1 PIK3CA KRAS
5 Decreased viability GR00221-A-3 10.09 FGFR3 HRAS TSC1 CDKN2A ERBB2
6 Decreased viability GR00221-A-4 10.09 CDKN2A PIK3CA ERBB2 DAPK1
7 Decreased viability GR00301-A 10.09 TSC1 KRAS CDH1
8 Decreased viability GR00342-S-1 10.09 DAPK1
9 Decreased viability GR00381-A-1 10.09 KRAS
10 Decreased cell migration GR00055-A-1 9.63 DAPK1 FGFR3 HRAS KRAS PIK3CA TSC1
11 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.35 CD44 DAPK1 ERBB2 FGFR3 HRAS

MGI Mouse Phenotypes related to Bladder Cancer, Somatic:

44 (show all 25)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.51 DAPK1 ERBB2 EZH2 FGF2 FGFR3 HRAS
2 cellular MP:0005384 10.49 FGF2 FGFR3 KRAS PIK3CA RASSF1 RB1
3 behavior/neurological MP:0005386 10.47 CD44 CDKN1A CDKN2A DAPK1 ERBB2 EZH2
4 cardiovascular system MP:0005385 10.46 RASSF1 RB1 TP53 TSC1 CDKN1A CDKN2A
5 growth/size/body region MP:0005378 10.42 CD44 CDH1 CDKN1A CDKN2A ERBB2 EZH2
6 endocrine/exocrine gland MP:0005379 10.4 ERBB2 EZH2 HRAS KRAS PIK3CA RASSF1
7 mortality/aging MP:0010768 10.4 CD44 CDH1 CDKN1A CDKN2A ERBB2 EZH2
8 integument MP:0010771 10.35 CD44 CDH1 CDKN1A CDKN2A ERBB2 EZH2
9 neoplasm MP:0002006 10.33 CD44 CDH1 CDKN1A CDKN2A ERBB2 EZH2
10 digestive/alimentary MP:0005381 10.3 CD44 CDH1 CDKN1A CDKN2A ERBB2 FGFR3
11 embryo MP:0005380 10.29 CDKN1A CDKN2A ERBB2 EZH2 KRAS PIK3CA
12 immune system MP:0005387 10.29 FGFR3 KRAS PIK3CA RASSF1 RB1 TP53
13 nervous system MP:0003631 10.28 TP53 TSC1 CD44 CDKN1A CDKN2A DAPK1
14 muscle MP:0005369 10.22 CD44 CDKN1A CDKN2A ERBB2 EZH2 FGF2
15 craniofacial MP:0005382 10.15 CDKN1A ERBB2 FGFR3 HRAS KRAS RB1
16 liver/biliary system MP:0005370 10.11 CD44 CDKN1A CDKN2A KRAS RASSF1 RB1
17 normal MP:0002873 10.11 RASSF1 RB1 TP53 CD44 CDH1 ERBB2
18 no phenotypic analysis MP:0003012 10.1 CDH1 CDKN1A CDKN2A EZH2 FGFR3 HRAS
19 limbs/digits/tail MP:0005371 10.07 CD44 CDKN1A ERBB2 FGFR3 KRAS RB1
20 renal/urinary system MP:0005367 10.06 CD44 CDKN1A DAPK1 FGFR3 HRAS KRAS
21 hearing/vestibular/ear MP:0005377 10.04 CDKN1A FGF2 FGFR3 KRAS RB1 TP53
22 reproductive system MP:0005389 10.03 RB1 TP53 TSC1 CD44 CDH1 CDKN1A
23 respiratory system MP:0005388 9.85 CD44 CDKN1A CDKN2A ERBB2 FGFR3 HRAS
24 skeleton MP:0005390 9.77 CD44 CDKN1A CDKN2A ERBB2 EZH2 FGF2
25 vision/eye MP:0005391 9.32 CD44 CDKN1A CDKN2A FGF2 FGFR3 KRAS

Drugs & Therapeutics for Bladder Cancer, Somatic

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Valstar 17 VALRUBICIN Anthra Pharmaceuticals Approved October 1998

Drugs for Bladder Cancer, Somatic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 20)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757 53477783
2
Fulvestrant Approved, Investigational Phase 2 129453-61-8 104741 17756771
3
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
4 Albumin-Bound Paclitaxel Phase 2
5 Antimitotic Agents Phase 2
6 Antineoplastic Agents, Hormonal Phase 2
7 Antineoplastic Agents, Phytogenic Phase 2
8 Estradiol 17 beta-cypionate Phase 2
9 Estradiol 3-benzoate Phase 2
10 Estradiol valerate Phase 2 979-32-8
11 Estrogen Antagonists Phase 2
12 Estrogen Receptor Antagonists Phase 2
13 Estrogens Phase 2
14 Hormone Antagonists Phase 2
15 Hormones Phase 2
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
17 Mitogens Phase 2
18 Polyestradiol phosphate Phase 2
19
Pancrelipase Approved 53608-75-6
20 pancreatin

Interventional clinical trials:


id Name Status NCT ID Phase
1 An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification Recruiting NCT01953926 Phase 2
2 Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program Recruiting NCT01772771

Search NIH Clinical Center for Bladder Cancer, Somatic

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bladder Cancer, Somatic cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bladder Cancer, Somatic:
Neo-Urinary Conduit
Embryonic/Adult Cultured Cells Related to Bladder Cancer, Somatic:
Neo-Urinary Conduit PMIDs: 22136657

Genetic Tests for Bladder Cancer, Somatic

Genetic tests related to Bladder Cancer, Somatic:

id Genetic test Affiliating Genes
1 Bladder Carcinoma 29
2 Bladder Cancer, Somatic 24 FGFR3 HRAS KRAS

Anatomical Context for Bladder Cancer, Somatic

Publications for Bladder Cancer, Somatic

Variations for Bladder Cancer, Somatic

UniProtKB/Swiss-Prot genetic disease variations for Bladder Cancer, Somatic:

66
id Symbol AA change Variation ID SNP ID
1 FGFR3 p.Arg248Cys VAR_004148 rs121913482
2 FGFR3 p.Ser249Cys VAR_004149 rs121913483
3 FGFR3 p.Gly370Cys VAR_004151 rs121913479
4 FGFR3 p.Lys650Glu VAR_004160 rs78311289
5 FGFR3 p.Lys650Gln VAR_018390 rs78311289

ClinVar genetic disease variations for Bladder Cancer, Somatic:

6 (show all 13)
id Gene Variation Type Significance SNP ID Assembly Location
1 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
2 HRAS NM_005343.3(HRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
3 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
4 RB1 RB1, IVS20, A-G, -2 single nucleotide variant Pathogenic
5 FGFR3 NM_000142.4(FGFR3): c.1111A> T (p.Ser371Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913484 GRCh37 Chromosome 4, 1806092: 1806092
6 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913483 GRCh37 Chromosome 4, 1803568: 1803568
7 FGFR3 NM_000142.4(FGFR3): c.1118A> G (p.Tyr373Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913485 GRCh37 Chromosome 4, 1806099: 1806099
8 FGFR3 NM_000142.4(FGFR3): c.1948A> C (p.Lys650Gln) single nucleotide variant Pathogenic/Likely pathogenic rs78311289 GRCh37 Chromosome 4, 1807889: 1807889
9 FGFR3 NM_000142.4(FGFR3): c.1108G> T (p.Gly370Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913479 GRCh37 Chromosome 4, 1806089: 1806089
10 TSC1 NM_000368.4(TSC1): c.1525C> T (p.Arg509Ter) single nucleotide variant Pathogenic rs118203542 GRCh37 Chromosome 9, 135781440: 135781440
11 TSC1 NM_000368.4(TSC1): c.2074C> T (p.Arg692Ter) single nucleotide variant Pathogenic rs118203631 GRCh37 Chromosome 9, 135779172: 135779172
12 TSC1 NM_000368.4(TSC1): c.663+1G> A single nucleotide variant Pathogenic rs118203419 GRCh37 Chromosome 9, 135797205: 135797205
13 TSC1 NM_000368.4(TSC1): c.664-1G> A single nucleotide variant Pathogenic rs118203423 GRCh37 Chromosome 9, 135796824: 135796824

Cosmic variations for Bladder Cancer, Somatic:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM45297 TP53 urinary tract,bladder,carcinoma,adenocarcinoma c.810T>G p.F270L 25
2 COSM10790 TP53 urinary tract,bladder,carcinoma,adenocarcinoma c.455C>T p.P152L 25
3 COSM11073 TP53 urinary tract,bladder,carcinoma,adenocarcinoma c.1024C>T p.R342* 25
4 COSM43778 TP53 urinary tract,bladder,carcinoma,adenocarcinoma c.713G>T p.C238F 25
5 COSM10727 TP53 urinary tract,bladder,carcinoma,adenocarcinoma c.438G>A p.W146* 25
6 COSM6932 TP53 urinary tract,bladder,carcinoma,adenocarcinoma c.733G>A p.G245S 25
7 COSM532 KRAS urinary tract,bladder,carcinoma,adenocarcinoma c.38G>A p.G13D 25
8 COSM520 KRAS urinary tract,bladder,carcinoma,adenocarcinoma c.35G>T p.G12V 25
9 COSM125370 urinary tract,bladder,carcinoma,adenocarcinoma c.1633G>A p.E545K 25

Copy number variations for Bladder Cancer, Somatic from CNVD:

7 (show top 50) (show all 98)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14770 1 110031964 110037890 Decreasing copy number GSTM1 Bladder cancer
2 16660 1 128900000 185800000 Gain Bladder cancer
3 18051 1 143699872 161705044 Gain Bladder cancer
4 36534 1 77068898 77170790 Loss Bladder cancer
5 51778 11 130615965 132678521 Loss Bladder cancer
6 53648 11 31517796 32050223 Loss Bladder cancer
7 58531 11 68323054 69297218 Gain Bladder cancer
8 67850 12 45466239 58591220 Gain Bladder cancer
9 75136 13 16000000 114142980 Copy number Bladder cancer
10 79497 13 72534137 72746128 Gain Bladder cancer
11 80757 13 97270228 100084626 Gain Bladder cancer
12 81341 14 101619009 102408085 Loss Bladder cancer
13 83177 14 19364851 19446107 Loss Bladder cancer
14 87829 14 77750645 79747731 Loss Bladder cancer
15 88246 14 88632756 89467875 Gain Bladder cancer
16 89915 15 19427350 19427409 Loss Bladder cancer
17 96847 15 95052889 95403459 Loss Bladder cancer
18 97491 16 10647794 11795463 Gain Bladder cancer
19 98997 16 22221235 32532138 Gain Bladder cancer
20 101674 16 45413780 45607724 Gain Bladder cancer
21 101856 16 46548299 69323131 Loss Bladder cancer
22 103047 16 5996067 6407032 Loss Bladder cancer
23 104499 16 69543004 70813070 Gain Bladder cancer
24 107647 17 1649595 1725887 Loss Bladder cancer
25 109050 17 24000000 38100000 Gain Bladder cancer
26 109225 17 24641926 27576519 Gain Bladder cancer
27 112300 17 38521264 78444637 Gain Bladder cancer
28 118108 17 7571719 7590863 Loss TP53 Bladder cancer
29 121742 18 467310 796252 Gain Bladder cancer
30 122814 18 61643142 67432063 Loss Bladder cancer
31 126424 19 18749534 19294814 Gain Bladder cancer
32 127148 19 278073 12616127 Gain Bladder cancer
33 127869 19 37856935 63485510 Gain Bladder cancer
34 135679 2 11956730 12796508 Gain Bladder cancer
35 135959 2 123437325 126399586 Loss Bladder cancer
36 138231 2 159948195 160120757 Loss Bladder cancer
37 141850 2 217249378 242464793 Loss Bladder cancer
38 146581 2 51236117 51635693 Loss Bladder cancer
39 147190 2 60966923 61033726 Loss Bladder cancer
40 147284 2 62081310 62298660 Loss Bladder cancer
41 148163 2 74469 50579433 Loss Bladder cancer
42 150320 2 9872881 10505097 Gain Bladder cancer
43 150974 20 157771 456225 Gain Bladder cancer
44 151125 20 17870221 18440898 Gain Bladder cancer
45 151502 20 22093371 26036562 Gain Bladder cancer
46 152003 20 28081598 47163674 Gain Bladder cancer
47 154726 20 48033501 54958791 Gain Bladder cancer
48 156571 20 61727753 62175139 Gain Bladder cancer
49 158507 21 33581851 34132794 Gain Bladder cancer
50 160744 22 16259597 16597551 Loss Bladder cancer

Expression for Bladder Cancer, Somatic

Search GEO for disease gene expression data for Bladder Cancer, Somatic.

Pathways for Bladder Cancer, Somatic

Pathways related to Bladder Cancer, Somatic according to GeneCards Suite gene sharing:

(show top 50) (show all 93)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.94 CDH1 CDKN1A CDKN2A ERBB2 FGF2 FGFR3
2
Show member pathways
13.62 CDH1 CDKN1A ERBB2 FGF2 FGFR3 HRAS
3
Show member pathways
13.58 ERBB2 EZH2 FGF2 FGFR3 HRAS KRAS
4
Show member pathways
13.54 CDH1 CDKN1A ERBB2 FGF2 FGFR3 HRAS
5
Show member pathways
13.49 CDKN1A ERBB2 FGF2 FGFR3 HRAS KRAS
6
Show member pathways
13.44 CD44 CDKN1A ERBB2 FGF2 FGFR3 HRAS
7
Show member pathways
13.35 CDH1 ERBB2 FGF2 FGFR3 HRAS KRAS
8
Show member pathways
12.99 CDKN1A HRAS KRAS PIK3CA RB1 TP53
9
Show member pathways
12.95 DAPK1 HRAS KRAS RB1 TP53
10
Show member pathways
12.93 CDH1 CDKN1A CDKN2A ERBB2 FGF2 FGFR3
11
Show member pathways
12.91 CDKN1A CDKN2A DAPK1 HRAS KRAS PIK3CA
12
Show member pathways
12.88 CDH1 ERBB2 HRAS KRAS PIK3CA TP53
13
Show member pathways
12.8 CDH1 FGF2 FGFR3 HRAS KRAS PIK3CA
14
Show member pathways
12.8 CDKN1A ERBB2 FGF2 FGFR3 HRAS KRAS
15 12.78 FGF2 FGFR3 HRAS KRAS TP53
16 12.71 FGF2 FGFR3 HRAS KRAS PIK3CA
17
Show member pathways
12.67 CDKN1A ERBB2 FGF2 HRAS KRAS PIK3CA
18
Show member pathways
12.66 FGF2 FGFR3 HRAS KRAS PIK3CA
19
Show member pathways
12.63 CDH1 ERBB2 HRAS KRAS PIK3CA RB1
20 12.63 CDKN1A FGF2 FGFR3 HRAS KRAS PIK3CA
21 12.59 CDKN1A CDKN2A MKI67 RB1 TP53
22
Show member pathways
12.58 ERBB2 FGFR3 HRAS KRAS PIK3CA TP53
23
Show member pathways
12.53 FGF2 FGFR3 HRAS KRAS PIK3CA
24
Show member pathways
12.52 CDKN1A HRAS PIK3CA TP53 TSC1
25
Show member pathways
12.52 ERBB2 FGFR3 HRAS KRAS PIK3CA TP53
26 12.5 CDKN1A CDKN2A HRAS KRAS PIK3CA RB1
27
Show member pathways
12.48 CDKN1A HRAS PIK3CA TP53 TSC1
28
Show member pathways
12.46 CD44 HRAS KRAS PIK3CA
29
Show member pathways
12.46 HRAS KRAS PIK3CA TSC1
30 12.46 CDH1 CDKN1A CDKN2A RB1 TP53
31
Show member pathways
12.43 CDKN1A CDKN2A RB1 TP53
32
Show member pathways
12.43 CDH1 CDKN1A ERBB2 HRAS KRAS PIK3CA
33
Show member pathways
12.41 CDKN1A CDKN2A RB1 TP53
34
Show member pathways
12.4 CDKN1A ERBB2 HRAS KRAS PIK3CA TP53
35 12.39 CD44 CDKN1A PIK3CA RB1 TP53
36 12.37 CD44 CDKN1A CDKN2A ERBB2 EZH2 FGFR3
37 12.37 CDH1 CDKN1A CDKN2A DAPK1 ERBB2 FGF2
38
Show member pathways
12.36 ERBB2 HRAS KRAS PIK3CA
39
Show member pathways
12.36 FGF2 FGFR3 HRAS KRAS PIK3CA
40 12.36 CDKN1A CDKN2A HRAS KRAS PIK3CA RB1
41
Show member pathways
12.31 CD44 HRAS KRAS PIK3CA
42
Show member pathways
12.3 FGF2 FGFR3 HRAS KRAS
43 12.28 CD44 CDKN1A ERBB2 FGF2 HRAS KRAS
44
Show member pathways
12.27 FGF2 FGFR3 HRAS KRAS PIK3CA
45 12.26 CDH1 CDKN1A KRAS TP53
46
Show member pathways
12.25 HRAS KRAS PIK3CA TP53
47 12.25 CDH1 KRAS RB1 TP53 TSC1
48
Show member pathways
12.24 HRAS KRAS PIK3CA TP53 TSC1
49
Show member pathways
12.24 CDKN1A ERBB2 FGFR3 KRAS RB1 TP53
50
Show member pathways
12.22 ERBB2 HRAS KRAS PIK3CA

GO Terms for Bladder Cancer, Somatic

Biological processes related to Bladder Cancer, Somatic according to GeneCards Suite gene sharing:

(show all 26)
id Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.95 ERBB2 FGF2 FGFR3 HRAS KRAS
2 leukocyte migration GO:0050900 9.93 CD44 HRAS KRAS PIK3CA
3 negative regulation of cell proliferation GO:0008285 9.91 CDKN1A CDKN2A HRAS RB1 TP53 TSC1
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.9 CD44 FGF2 FGFR3 HRAS
5 negative regulation of gene expression GO:0010629 9.89 CDKN1A EZH2 HRAS RB1
6 phosphatidylinositol phosphorylation GO:0046854 9.83 ERBB2 FGF2 FGFR3 PIK3CA
7 epidermal growth factor receptor signaling pathway GO:0007173 9.78 HRAS KRAS PIK3CA
8 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.75 FGF2 FGFR3 PIK3CA
9 phosphatidylinositol-mediated signaling GO:0048015 9.72 ERBB2 FGF2 FGFR3 PIK3CA TP53
10 intrinsic apoptotic signaling pathway GO:0097193 9.71 CDKN1A HRAS TP53
11 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.71 ERBB2 FGF2 FGFR3 PIK3CA
12 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.69 CDKN1A EZH2 RB1
13 cellular response to gamma radiation GO:0071480 9.67 CDKN1A HRAS TP53
14 cellular senescence GO:0090398 9.63 CDKN1A CDKN2A HRAS
15 response to isolation stress GO:0035900 9.62 HRAS KRAS
16 positive regulation of cellular senescence GO:2000774 9.62 CDKN2A KRAS
17 negative regulation of immature T cell proliferation in thymus GO:0033088 9.57 CDKN2A ERBB2
18 signal transduction by p53 class mediator GO:0072331 9.56 CDKN1A TP53
19 ERBB2 signaling pathway GO:0038128 9.56 ERBB2 HRAS KRAS PIK3CA
20 positive regulation of MAP kinase activity GO:0043406 9.55 ERBB2 EZH2 FGF2 HRAS KRAS
21 replicative senescence GO:0090399 9.54 CDKN1A CDKN2A TP53
22 cell cycle arrest GO:0007050 9.5 CDKN1A CDKN2A HRAS RASSF1 RB1 TP53
23 Ras protein signal transduction GO:0007265 9.23 CDKN1A CDKN2A FGF2 HRAS KRAS RASSF1
24 phosphorylation GO:0016310 10.09 CDKN1A CDKN2A DAPK1 ERBB2 FGFR3 PIK3CA
25 cell cycle GO:0007049 10.06 CDKN1A CDKN2A MKI67 RASSF1 RB1 TP53
26 apoptotic process GO:0006915 10.02 CDKN2A DAPK1 FGFR3 HRAS KRT20 RB1

Molecular functions related to Bladder Cancer, Somatic according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.73 CDKN1A CDKN2A DAPK1 ERBB2 FGFR3 PIK3CA
2 protein binding GO:0005515 9.62 CD44 CDH1 CDKN1A CDKN2A DAPK1 ERBB2
3 1-phosphatidylinositol-3-kinase activity GO:0016303 9.33 FGF2 FGFR3 PIK3CA
4 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.32 CDKN1A CDKN2A
5 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.26 ERBB2 FGF2 FGFR3 PIK3CA

Sources for Bladder Cancer, Somatic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....